Monoclonal antibody CA208-cytorhodin-S conjugateAlternative Names: Cyt-S-CA208
Latest Information Update: 29 May 1997
At a glance
- Originator Aventis Japan
- Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 May 1997 Changed drug development phase to discontinued (preclinical)
- 29 May 1997 Discontinued-Preclinical for Cancer in Japan (Unknown route)
- 22 May 1997 New profile